A study finds that the anti-obesity and diabetes drug semaglutide could cost as little as $3 per month once it goes off patent. Currently sold as Ozempic and Wegovy for around $200 monthly in the US, generic production could make the treatment affordable in low- and middle-income countries, potentially improving access for millions suffering from obesity and Type 2 diabetes.